Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Brief Summary: The purpose of this study is to evaluate the dose response (efficacy), pharmacodynamic response, pharmacokinetics, safety, and tolerability of orally administered AKB-6548 in pre-dialysis participants with anemia with repeat dosing for 42 days.


Options:
A: Arm Label: Desidustat oral tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desidustat Oral Tablet | Arm Label: Epoetin Injection; Type: EXPERIMENTAL; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: Desidustat Oral Tablet; Assigned to Arm(s): Desidustat oral tablet | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin Injection
B: Arm Label: AKB-6548 240 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: AKB-6548 370 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: AKB-6548 500 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: AKB-6548 630 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AKB-6548; Assigned to Arm(s): AKB-6548 240 mg, AKB-6548 370 mg, AKB-6548 500 mg, AKB-6548 630 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Participants receiving Daprodustat; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat, Drug: Acetylcholine, Drug: Sodium nitroprusside, Drug: L-N-monomethyl arginine acetate (L-NMMA) | Arm Label: Participants receiving Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa, Drug: Acetylcholine, Drug: Sodium nitroprusside, Drug: L-N-monomethyl arginine acetate (L-NMMA) | Intervention Type: DRUG; Name: Daprodustat; Assigned to Arm(s): Participants receiving Daprodustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Participants receiving Darbepoetin alfa | Intervention Type: DRUG; Name: Acetylcholine; Assigned to Arm(s): Participants receiving Daprodustat, Participants receiving Darbepoetin alfa | Intervention Type: DRUG; Name: Sodium nitroprusside; Assigned to Arm(s): Participants receiving Daprodustat, Participants receiving Darbepoetin alfa | Intervention Type: DRUG; Name: L-N-monomethyl arginine acetate (L-NMMA); Assigned to Arm(s): Participants receiving Daprodustat, Participants receiving Darbepoetin alfa
D: Arm Label: Dose 1 JTZ-951 or Placebo; Type: EXPERIMENTAL; Interventions: Drug: JTZ-951, Drug: Placebo | Arm Label: Dose 2 JTZ-951 or Placebo; Type: EXPERIMENTAL; Interventions: Drug: JTZ-951, Drug: Placebo | Arm Label: Dose 3 JTZ-951 or Placebo; Type: EXPERIMENTAL; Interventions: Drug: JTZ-951, Drug: Placebo | Arm Label: Dose 4 JTZ-951 or Placebo; Type: EXPERIMENTAL; Interventions: Drug: JTZ-951, Drug: Placebo | Intervention Type: DRUG; Name: JTZ-951; Assigned to Arm(s): Dose 1 JTZ-951 or Placebo, Dose 2 JTZ-951 or Placebo, Dose 3 JTZ-951 or Placebo, Dose 4 JTZ-951 or Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Dose 1 JTZ-951 or Placebo, Dose 2 JTZ-951 or Placebo, Dose 3 JTZ-951 or Placebo, Dose 4 JTZ-951 or Placebo

Answer: B